Total
0
Shares
Stuart Perry / Shutterstock.com
Market Herald logo

Subscribe

Be the first with the news that moves the market

Jatenergy released a high performing quarterly report and announcing a nine-month gross revenue to 31 March of $53.9 million.

Jatenergy is a company specialising in milk formula sales from Australia to China.

Gross revenue for the March 2019 quarter was $20.53m.

Jatenergy firmly stated the strong sales performance comes from a recent partnership with Chinese distributors HIT Crown. HIT Crown manages online medicine sales platform China Golden.

China Golden services over one million pharmaceutical companies, hospitals and consumers.

The company also announced two new sales agreements for its products. A five-year agreement with Guangzhou Niurui Trading Company has been signed.

This agreement will see Jatenergy formulas distributed into 150 Babemax maternal retail outlets.

Guangzhou will purchase 1.5 million tins of Neurio Lactoferrin milk powder. Jatenergy also signed a one-year agreement to sell through online store Bon Bon and its Wanwustore subsidiary.

The company expects to begin sales of a new milk formula for adults in May this year. Jatenergy also secured a trademark on Green Forest’s NSW sourced canola oil, to be released in May also.

Jatenergy’s ‘Golden Koala’ product range is currently selling well in the Chinese market. The company continues plans to establish a manufacturing plant in Australia.

Jatenergy rose 1.72 percent in the ASX today.

Please see the announcement attached

JAT by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.